Stem Cells + Monoclonal Antibodies for Alzheimer's Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to test if adding one infusion of (Human Mesenchymal Stem Cells) hMSCs to the treatment with standard of care (SOC) monoclonal antibodies (mAb) will stabilize the rate of cognitive and functional decline associated with mild Alzheimer's Disease.
Who Is on the Research Team?
Bernard S. Baumel, MD
Principal Investigator
University of Miami
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive one infusion of 25 million human mesenchymal stem cells in addition to standard of care monoclonal antibodies
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Human Mesenchymal Stem Cells
- Monoclonal Antibodies
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Patients will receive one infusion of 25 million of human mesenchymal stem cells in the vein.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bernard (Barry) Baumel
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.